Clomiphene (Clomid) vs Oxandrolone (Anavar)

Mechanism

Clomiphene citrate is a racemic mixture of enclomiphene (trans-isomer, estrogen antagonist) and zuclomiphene (cis-isomer, weak estrogen agonist) that acts as a selective estrogen receptor modulator (SERM). It competitively occupies hypothalamic estrogen receptors, blocking the negative feedback of estradiol on GnRH pulse frequency. This disinhibition increases pulsatile GnRH release, stimulating anterior pituitary gonadotrope secretion of both LH and FSH, which in turn drives testicular testosterone synthesis and spermatogenesis. The zuclomiphene isomer has a much longer half-life (~30 days vs. ~10 days for enclomiphene), leading to tissue accumulation with chronic use.

Standard Dosing

Research indicates 25-50 mg daily or every other day for PCT/HPTA restart protocols. Clinical hypogonadism treatment: 25-50 mg daily.

Timing

Take at the same time daily. Evening dosing may reduce perception of visual side effects. No food timing requirements.

Cycle Duration

PCT protocols: 4-8 weeks. Long-term SERM monotherapy: 3-12 months with periodic reassessment. Zuclomiphene accumulation is a concern beyond 6 months.

Side Effects

• Visual disturbances (blurred vision, floaters, light sensitivity — due to zuclomiphene accumulation)
• Mood swings and emotional lability
• Headache
• Nausea
• Hot flashes
• Gynecomastia (paradoxical, from zuclomiphene's estrogenic activity)
• Elevated estradiol (zuclomiphene accumulation)

Contraindications

• Active liver disease or hepatic dysfunction
• Undiagnosed abnormal uterine bleeding (if prescribed to females)
• Ovarian cysts (females)
• Known hypersensitivity to clomiphene
• Pituitary tumor
• Primary hypogonadism (testicular failure — clomiphene only works in secondary hypogonadism)

Best Stacking Partners

Mechanism

Oxandrolone is a synthetic 17-alpha-alkylated dihydrotestosterone (DHT) derivative with a modified A-ring (replacement of C2 with an oxygen atom) that confers high anabolic-to-androgenic ratio (~10:1). It enhances protein synthesis by activating the androgen receptor while strongly binding sex hormone-binding globulin (SHBG), increasing free testosterone fraction. Oxandrolone directly stimulates phosphocreatine synthesis in skeletal muscle and has demonstrated anti-catabolic effects through cortisol receptor antagonism. In burn patients, it reverses catabolism by restoring the IGF-1/IGFBP-3 axis.

Standard Dosing

Research indicates 5-20 mg/day orally for therapeutic/recovery applications. Clinical burn protocols use 0.1 mg/kg twice daily.

Timing

Split into 2 doses (morning and evening) due to 9-hour half-life. Take with food to reduce GI discomfort.

Cycle Duration

Typical therapeutic cycles: 6-12 weeks. Clinical burn protocols have extended to 1 year+ with liver monitoring. Limit cycle length to minimize hepatic stress.

Side Effects

• Hepatotoxicity (dose and duration dependent — mild with therapeutic doses)
• Lipid profile disruption (significant HDL suppression, LDL elevation)
• Suppression of endogenous testosterone (dose dependent)
• Virilization in females at higher doses
• Headache
• Nausea
• Potential hair loss in genetically susceptible individuals

Contraindications

• Prostate cancer
• Breast cancer in males
• Hypercalcemia
• Severe hepatic impairment or active liver disease
• Nephrotic syndrome
• Pregnancy (Category X)

Best Stacking Partners